Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath’s London Office Moves to 100 Cheapside

Read More

People

Timothy G.
Cameron

Partner, Litigation

tcameron@cravath.com
  • New York+1-212-474-1120
    • E-mail
    • Twitter
    • Facebook
    • LinkedIn
  • PDF
  • Vcard
  • Overview
  • Credentials
  • Featured Work
  • News & Insights

Praised by clients as a “fearless leader” with a “great courtroom presence,” Tim Cameron frequently handles his clients’ most challenging and business‑critical disputes in litigation throughout the U.S., as well as in arbitration tribunals domestically and internationally.  (Chambers USA)

Mr. Cameron is an experienced trial lawyer, with additional extensive experience handling antitrust, securities, shareholder derivative, M&A, and product liability claims, as well as regulatory matters. He is among the few litigators to have taken a securities case through trial, having handled three such trials for Vivendi in some of the most significant and complex securities actions in recent history. More recently, Mr. Cameron led the trial team that successfully defended the Louis Dreyfus Company and its subsidiary Imperial Sugar against the Department of Justice’s (DOJ) effort to block the sale of that company to U.S. Sugar—a significant win, that was unanimously affirmed on appeal, in one of the most closely watched antitrust cases under the Biden Administration.

Mr. Cameron also has deep experience in a wide variety of complex commercial matters, with a focus on complicated cross‑border issues particularly for non-U.S. clients.

Examples of Mr. Cameron’s current and recent cases include:

  • Represented 260 Twelfth Avenue Holdings, LLC in litigation filed in New York federal court to obtain just compensation for the taking of property through eminent domain by the National Railroad Passenger Corporation (Amtrak) in connection with the Hudson Tunnel Project in New York City, reaching a settlement shortly before a scheduled trial.
  • Led post-trial and appellate proceedings before the Fifth Circuit for Louis Dreyfus in an action brought by the Port of Houston Authority alleging Louis Dreyfus breached its agreement for the lease of a grain elevator, railroad system and surrounding infrastructure from the Port Authority. The parties reached a settlement to resolve the action.
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest acquisition in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Louis Dreyfus and its subsidiary Imperial Sugar in an action brought by the DOJ in Delaware federal court seeking to enjoin U.S. Sugar’s proposed acquisition of Imperial Sugar from Louis Dreyfus. In September 2022, the court issued a post‑trial ruling in favor of the defendants, denying the DOJ’s request for an injunction to block the acquisition, and the Third Circuit unanimously affirmed the ruling in July 2023.
  • Representing Stanley Black & Decker and current and former officers in putative class action securities litigation, as well as related consolidated shareholder derivative actions, in Connecticut federal court alleging the company made false and misleading statements concerning its tool manufacturing business.
  • Representation of Epic Games in antitrust litigation against Google, alleging anticompetitive behavior in the distribution of mobile apps and the handling of in‑app payments. Following a multiweek trial, a jury unanimously ruled in favor of Epic on all counts. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week,” and received an Impact Case Award from Benchmark Litigation.
  • Representing defendants in a confidential International Chamber of Commerce (ICC) arbitration involving cross-border claims in excess of $1 billion.
  • Representing Spirits International in its dispute against the Russian Federation over the ownership of the famous Stolichnaya vodka trademarks.
  • Represented Micro Focus International (now OpenText) and certain individual defendants in securing a favorable settlement shortly before trial in putative securities class action litigation filed in New York federal court and California state court concerning its $8.8 billion acquisition of certain of Hewlett Packard Enterprise’s software assets. 
  • Represented Westpac Banking Corporation in a putative class action asserting, inter alia, antitrust, the Racketeer Influenced and Corrupt Organizations Act (RICO) and Commodity Exchange Act claims premised upon alleged manipulation of the Australian Bank Bill Swap Reference Rate (BBSW).
  • Represented Westpac Banking Corporation and its current chief executive officer in putative class action securities litigation filed in Oregon federal court alleging that Westpac failed timely to disclose that it had failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre (AUSTRAC), contrary to Australian law.
  • Represented DuPont in an antitrust class action lawsuit filed in Maryland federal court alleging that DuPont and various co‑defendants conspired to fix the price of titanium dioxide. 
  • Represented the Swedish company Folksam ömsesidig livförsäkring and won the dismissal of an action asserting RICO claims premised upon alleged violations of Swedish financial regulations, fraud and money laundering, as well as claims under the Computer Fraud and Abuse Act and New York common law.
  • Represented Chemed Corporation and various individual defendants in consolidated shareholder derivative litigation in Delaware federal court arising from alleged improper billing of Medicare and Medicaid. Mr. Cameron obtained the dismissal of that litigation once, without prejudice, and, following repleading, secured final dismissal of the matter with prejudice as to all defendants. He also represented the company in related securities class action litigation, which settled.
  • Represented Novartis Pharmaceuticals in a civil enforcement action filed in New York federal court by the U.S. Attorney’s Office for the Southern District of New York alleging violations of the False Claims Act and Anti‑Kickback Statute.
  • Represented Colgate‑Palmolive in several product liability lawsuits around the country, including two jury trials in California state court, one of which resulted in a unanimous jury verdict in Colgate-Palmolive’s favor, while the other was settled on favorable terms. Another case in South Carolina state court settled two days into trial.
  • Represented Vivendi, S.A. for over a decade in several matters, including (a) securities class action litigation which culminated in a four‑month jury trial—the first and only so‑called “foreign cubed” case to have gone to trial; (b) a four‑week jury trial over securities and contract claims in a suit brought by Liberty Media relating, in part, to a transaction involving USA Networks; and (c) a two‑day bench trial in a securities fraud case brought by GAMCO Investors—the first public market purchase case in which the presumption of reliance was successfully rebutted at a trial on the merits.
  • Represented AWB Limited (now Agrium Asia Pacific Ltd.) and won dismissals at the motion to dismiss stage of five separate actions relating to AWB’s participation in the U.N. Oil for Food Programme in Iraq and involving various claims including antitrust, civil RICO, Foreign Corrupt Practices Act (FCPA) and Alien Tort Statute claims.

Mr. Cameron’s clients commend him as a “powerful litigator” and “have nothing but the highest praise” for his work. (Best Lawyers Best Law Firms; Chambers USA) He has been recognized by Chambers USA for his work in general commercial litigation. Mr. Cameron has been selected as one of Lawdragon’s “500 Leading Lawyers in America” for over a decade, and named to several of the publication’s lists, including “100 Lawyers You Need to Know in Securities Litigation,” “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Global Litigators.” Lawdragon also named him a nationwide “Legend” in 2020.

Among other accolades, he has been recognized by Benchmark Litigation every year since 2009, including, in recent years, as a “Litigation Star” in the New York area. Mr. Cameron has been repeatedly recommended by The Legal 500 US for securities litigation and commercial litigation, as well as by The Best Lawyers in America for securities litigation, commercial litigation and international arbitration. 

Based on Mr. Cameron’s successful defense of Vivendi in the GAMCO case, Cravath was named the number one “Heavyweight Champion” in Litigation in the Financial Times 2013 U.S. Innovative Lawyers Report.

Mr. Cameron is a member of the Board of the New York International Arbitration Center, the Court of the London Court of International Arbitration (LCIA), and the Litigation Committee of the International Bar Association. 

Mr. Cameron has authored the U.S. chapter in the book The Class Action Law Review since 2017.  He has authored a chapter in the book The Dispute Resolution Review since 2010.  He was also a contributing editor of Chambers Legal Practice Guide: Litigation 2014.

Mr. Cameron was born in Auckland, New Zealand. He received an LL.B.(Hons)/B.Com in 1994 from the University of Auckland, New Zealand; an M.ComLaw with first class honors in 1997 from the University of Auckland, New Zealand; and an LL.M. in 1998 from the University of Chicago Law School. From February 1994 to September 1997, he practiced law at Russell McVeagh McKenzie Bartleet & Co. in Auckland, New Zealand.

Mr. Cameron joined Cravath in 1998 and was elected a partner in 2004.

Mr. Cameron is an experienced trial lawyer, with additional extensive experience handling antitrust, securities, shareholder derivative, M&A, and product liability claims, as well as regulatory matters. He is among the few litigators to have taken a securities case through trial, having handled three such trials for Vivendi in some of the most significant and complex securities actions in recent history. More recently, Mr. Cameron led the trial team that successfully defended the Louis Dreyfus Company and its subsidiary Imperial Sugar against the Department of Justice’s (DOJ) effort to block the sale of that company to U.S. Sugar—a significant win, that was unanimously affirmed on appeal, in one of the most closely watched antitrust cases under the Biden Administration.

Mr. Cameron also has deep experience in a wide variety of complex commercial matters, with a focus on complicated cross‑border issues particularly for non-U.S. clients.

Examples of Mr. Cameron’s current and recent cases include:

  • Represented 260 Twelfth Avenue Holdings, LLC in litigation filed in New York federal court to obtain just compensation for the taking of property through eminent domain by the National Railroad Passenger Corporation (Amtrak) in connection with the Hudson Tunnel Project in New York City, reaching a settlement shortly before a scheduled trial.
  • Led post-trial and appellate proceedings before the Fifth Circuit for Louis Dreyfus in an action brought by the Port of Houston Authority alleging Louis Dreyfus breached its agreement for the lease of a grain elevator, railroad system and surrounding infrastructure from the Port Authority. The parties reached a settlement to resolve the action.
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest acquisition in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Louis Dreyfus and its subsidiary Imperial Sugar in an action brought by the DOJ in Delaware federal court seeking to enjoin U.S. Sugar’s proposed acquisition of Imperial Sugar from Louis Dreyfus. In September 2022, the court issued a post‑trial ruling in favor of the defendants, denying the DOJ’s request for an injunction to block the acquisition, and the Third Circuit unanimously affirmed the ruling in July 2023.
  • Representing Stanley Black & Decker and current and former officers in putative class action securities litigation, as well as related consolidated shareholder derivative actions, in Connecticut federal court alleging the company made false and misleading statements concerning its tool manufacturing business.
  • Representation of Epic Games in antitrust litigation against Google, alleging anticompetitive behavior in the distribution of mobile apps and the handling of in‑app payments. Following a multiweek trial, a jury unanimously ruled in favor of Epic on all counts. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week,” and received an Impact Case Award from Benchmark Litigation.
  • Representing defendants in a confidential International Chamber of Commerce (ICC) arbitration involving cross-border claims in excess of $1 billion.
  • Representing Spirits International in its dispute against the Russian Federation over the ownership of the famous Stolichnaya vodka trademarks.
  • Represented Micro Focus International (now OpenText) and certain individual defendants in securing a favorable settlement shortly before trial in putative securities class action litigation filed in New York federal court and California state court concerning its $8.8 billion acquisition of certain of Hewlett Packard Enterprise’s software assets. 
  • Represented Westpac Banking Corporation in a putative class action asserting, inter alia, antitrust, the Racketeer Influenced and Corrupt Organizations Act (RICO) and Commodity Exchange Act claims premised upon alleged manipulation of the Australian Bank Bill Swap Reference Rate (BBSW).
  • Represented Westpac Banking Corporation and its current chief executive officer in putative class action securities litigation filed in Oregon federal court alleging that Westpac failed timely to disclose that it had failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre (AUSTRAC), contrary to Australian law.
  • Represented DuPont in an antitrust class action lawsuit filed in Maryland federal court alleging that DuPont and various co‑defendants conspired to fix the price of titanium dioxide. 
  • Represented the Swedish company Folksam ömsesidig livförsäkring and won the dismissal of an action asserting RICO claims premised upon alleged violations of Swedish financial regulations, fraud and money laundering, as well as claims under the Computer Fraud and Abuse Act and New York common law.
  • Represented Chemed Corporation and various individual defendants in consolidated shareholder derivative litigation in Delaware federal court arising from alleged improper billing of Medicare and Medicaid. Mr. Cameron obtained the dismissal of that litigation once, without prejudice, and, following repleading, secured final dismissal of the matter with prejudice as to all defendants. He also represented the company in related securities class action litigation, which settled.
  • Represented Novartis Pharmaceuticals in a civil enforcement action filed in New York federal court by the U.S. Attorney’s Office for the Southern District of New York alleging violations of the False Claims Act and Anti‑Kickback Statute.
  • Represented Colgate‑Palmolive in several product liability lawsuits around the country, including two jury trials in California state court, one of which resulted in a unanimous jury verdict in Colgate-Palmolive’s favor, while the other was settled on favorable terms. Another case in South Carolina state court settled two days into trial.
  • Represented Vivendi, S.A. for over a decade in several matters, including (a) securities class action litigation which culminated in a four‑month jury trial—the first and only so‑called “foreign cubed” case to have gone to trial; (b) a four‑week jury trial over securities and contract claims in a suit brought by Liberty Media relating, in part, to a transaction involving USA Networks; and (c) a two‑day bench trial in a securities fraud case brought by GAMCO Investors—the first public market purchase case in which the presumption of reliance was successfully rebutted at a trial on the merits.
  • Represented AWB Limited (now Agrium Asia Pacific Ltd.) and won dismissals at the motion to dismiss stage of five separate actions relating to AWB’s participation in the U.N. Oil for Food Programme in Iraq and involving various claims including antitrust, civil RICO, Foreign Corrupt Practices Act (FCPA) and Alien Tort Statute claims.

Mr. Cameron’s clients commend him as a “powerful litigator” and “have nothing but the highest praise” for his work. (Best Lawyers Best Law Firms; Chambers USA) He has been recognized by Chambers USA for his work in general commercial litigation. Mr. Cameron has been selected as one of Lawdragon’s “500 Leading Lawyers in America” for over a decade, and named to several of the publication’s lists, including “100 Lawyers You Need to Know in Securities Litigation,” “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Global Litigators.” Lawdragon also named him a nationwide “Legend” in 2020.

Among other accolades, he has been recognized by Benchmark Litigation every year since 2009, including, in recent years, as a “Litigation Star” in the New York area. Mr. Cameron has been repeatedly recommended by The Legal 500 US for securities litigation and commercial litigation, as well as by The Best Lawyers in America for securities litigation, commercial litigation and international arbitration. 

Based on Mr. Cameron’s successful defense of Vivendi in the GAMCO case, Cravath was named the number one “Heavyweight Champion” in Litigation in the Financial Times 2013 U.S. Innovative Lawyers Report.

Mr. Cameron is a member of the Board of the New York International Arbitration Center, the Court of the London Court of International Arbitration (LCIA), and the Litigation Committee of the International Bar Association. 

Mr. Cameron has authored the U.S. chapter in the book The Class Action Law Review since 2017.  He has authored a chapter in the book The Dispute Resolution Review since 2010.  He was also a contributing editor of Chambers Legal Practice Guide: Litigation 2014.

Mr. Cameron was born in Auckland, New Zealand. He received an LL.B.(Hons)/B.Com in 1994 from the University of Auckland, New Zealand; an M.ComLaw with first class honors in 1997 from the University of Auckland, New Zealand; and an LL.M. in 1998 from the University of Chicago Law School. From February 1994 to September 1997, he practiced law at Russell McVeagh McKenzie Bartleet & Co. in Auckland, New Zealand.

Mr. Cameron joined Cravath in 1998 and was elected a partner in 2004.

Education

  • LL.M., 1998, University of Chicago Law School
  • M.ComLaw, 1997, Auckland University - Faculty of Law
    First Class Honors
  • LL.B., 1994, Auckland University - Faculty of Law
  • B.Com., 1994, Auckland University - Faculty of Law

Admitted In

  • New York

Professional Affiliations

American Bar Association

Auckland District Law Society

International Bar Association

New York City Bar Association

New York State Bar Association

New Zealand Law Society

Rankings

Benchmark Litigation

  • Litigation Star ‑ New York (2025‑2016)
  • Future Star (2015‑2009)

Best Lawyers in America

  • Commercial Litigation (2025‑2014)
  • International Arbitration – Commercial (2025, 2024)
  • Litigation - Securities (2025-2019)

Chambers USA

  • Litigation: General Commercial - New York (2024)

Lawdragon

  • Legends of the 500 Leading Lawyers in America (2020)
  • 500 Leading Global Litigators (2024, 2023)
  • 100 Lawyers You Need to Know in Securities Litigation
  • 500 Leading Global Antitrust & Competition Lawyers (2025)
  • 500 Leading Lawyers in America (2025‑2011, 2008)
  • 500 Leading Litigators in America (2025, 2024, 2023)

The Legal 500 US

  • Financial Services:  Litigation (2022)
  • General Commercial (2024, 2023, 2015)
  • Securities Litigation (2023, 2019, 2018, 2017)

Super Lawyers ‑ New York

  • Business Litigation (2021‑2014)

Cleary Memorial Prize (New Zealand), 1995

Deals & Cases

October 15, 2024

Epic Games Wins Post‑Trial Injunction in Antitrust Case Against Google

On October 7, 2024, the U.S. District Court for the Northern District of California entered a post‑trial order in favor of Cravath client Epic Games imposing a nationwide three‑year permanent injunction against Google. The injunction, which follows Epic’s jury trial win against Google last year, prohibits Google from paying competitors not to compete and requires Google to distribute alternative app stores on the Google Play Store and provide alternative app stores with access to the Google Play Store’s catalog of apps.

Deals & Cases

December 19, 2023

Epic Games Defeats Google in Antitrust Trial Victory

On December 11, 2023, a jury unanimously ruled in favor of Cravath client Epic Games (“Epic”) on all counts in its closely watched antitrust case against Google in the U.S. District Court for the Northern District of California, determining—after a multiweek trial—that Google has engaged in anticompetitive behavior in the distribution of mobile apps and in the handling of in‑app payments.

Deals & Cases

September 11, 2023

Amgen Successfully Defends Against FTC Challenge, Securing Clearance for its $27.8 Billion Acquisition of Horizon Therapeutics

Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”

Deals & Cases

July 14, 2023

Louis Dreyfus Company and Imperial Sugar Company Win Appellate Victory Over DOJ

On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.

Deals & Cases

July 07, 2023

Cravath and NYU Veterans Legal Services Project Secure Win for Veteran Seeking Disability Compensation

On May 31, 2023, Judge Greenberg of the U.S. Court of Appeals for Veterans Claims ruled in favor of veteran and Cravath pro bono client Jason D. McCoy.

Activities

March 10, 2025

Benchmark Litigation Names Cravath “Antitrust Firm of the Year” at its 2025 U.S. Awards

On March 6, 2025, Benchmark Litigation honored Cravath at the publication’s sixteenth annual U.S. Awards, which was held in New York City in honor of “the elite litigators and the firms that set the standard for excellence.” The Firm was awarded Benchmark Litigation’s “Antitrust Firm of the Year” award. Cravath partners David R. Marriott and Timothy G. Cameron accepted the award on behalf of the Firm.

Publications

February 26, 2025

Tim Cameron Authors U.S. Chapter of Lexology In‑Depth’s “Dispute Resolution - Edition 17”

Cravath partner Timothy G. Cameron and associate Michael Cheng authored the United States chapter of Lexology In‑Depth’s “Dispute Resolution - Edition 17,” which was published on January 24, 2025. The chapter provides an in‑depth overview of the U.S. federal and state court systems, covering how district, bankruptcy and other special trial courts are organized, as well as the procedural rules applicable in federal courts. The chapter also reviews several notable U.S. Supreme Court decisions from 2024.

Activities

February 07, 2025

Tim Cameron Speaks at 2025 Swiss Arbitration Summit

On January 29, 2025, Cravath partner Timothy G. Cameron participated in the 2025 Swiss Arbitration Summit, which was hosted by the Swiss Arbitration Association from January 29-31 in Zurich. Tim spoke on a panel entitled “Interim Relief in Support of Arbitration: Coordination of Cross-Border Remedies Before State Courts and Arbitral Tribunals,” which brought together arbitration practitioners from multiple jurisdictions to examine the types of interim relief that can be obtained from state courts and arbitral tribunals in order to preserve the status quo until a final award is rendered.

Activities

December 19, 2023

Cravath Team Named “Litigators of the Week” by The Am Law Litigation Daily for Epic Games’ Antitrust Trial Win Defeating Google

On December 15, 2023, The Am Law Litigation Daily featured a Cravath team, led by partners Gary A. Bornstein, Lauren A. Moskowitz and Yonatan Even, as “Litigators of the Week” for its representation of client Epic Games in an antitrust trial win against Google in the U.S. District Court for the Northern District of California. Following a multi‑week trial, on December 11, 2023, a jury unanimously ruled in Epic Games’ favor on all counts, determining that Google has engaged in anticompetitive behavior in the distribution of mobile apps and in the handling of in‑app payments.

Activities

September 08, 2023

Cravath Team Named “Litigators of the Week” by The Am Law Litigation Daily for Successful Defense of Amgen Against FTC’s Challenge to Acquisition of Horizon Therapeutics

On September 8, 2023, The Am Law Litigation Daily featured a Cravath team, led by partners David R. Marriott and Timothy G. Cameron and of counsel Jesse M. Weiss, as “Litigators of the Week” for its successful defense of Amgen, one of the world’s largest biopharmaceutical companies, against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that ends all litigation and clears the path for the transaction to close.

Praised by clients as a “fearless leader” with a “great courtroom presence,” Tim Cameron frequently handles his clients’ most challenging and business‑critical disputes in litigation throughout the U.S., as well as in arbitration tribunals domestically and internationally.  (Chambers USA)

Mr. Cameron is an experienced trial lawyer, with additional extensive experience handling antitrust, securities, shareholder derivative, M&A, and product liability claims, as well as regulatory matters. He is among the few litigators to have taken a securities case through trial, having handled three such trials for Vivendi in some of the most significant and complex securities actions in recent history. More recently, Mr. Cameron led the trial team that successfully defended the Louis Dreyfus Company and its subsidiary Imperial Sugar against the Department of Justice’s (DOJ) effort to block the sale of that company to U.S. Sugar—a significant win, that was unanimously affirmed on appeal, in one of the most closely watched antitrust cases under the Biden Administration.

Mr. Cameron also has deep experience in a wide variety of complex commercial matters, with a focus on complicated cross‑border issues particularly for non-U.S. clients.

Examples of Mr. Cameron’s current and recent cases include:

  • Represented 260 Twelfth Avenue Holdings, LLC in litigation filed in New York federal court to obtain just compensation for the taking of property through eminent domain by the National Railroad Passenger Corporation (Amtrak) in connection with the Hudson Tunnel Project in New York City, reaching a settlement shortly before a scheduled trial.
  • Led post-trial and appellate proceedings before the Fifth Circuit for Louis Dreyfus in an action brought by the Port of Houston Authority alleging Louis Dreyfus breached its agreement for the lease of a grain elevator, railroad system and surrounding infrastructure from the Port Authority. The parties reached a settlement to resolve the action.
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest acquisition in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Louis Dreyfus and its subsidiary Imperial Sugar in an action brought by the DOJ in Delaware federal court seeking to enjoin U.S. Sugar’s proposed acquisition of Imperial Sugar from Louis Dreyfus. In September 2022, the court issued a post‑trial ruling in favor of the defendants, denying the DOJ’s request for an injunction to block the acquisition, and the Third Circuit unanimously affirmed the ruling in July 2023.
  • Representing Stanley Black & Decker and current and former officers in putative class action securities litigation, as well as related consolidated shareholder derivative actions, in Connecticut federal court alleging the company made false and misleading statements concerning its tool manufacturing business.
  • Representation of Epic Games in antitrust litigation against Google, alleging anticompetitive behavior in the distribution of mobile apps and the handling of in‑app payments. Following a multiweek trial, a jury unanimously ruled in favor of Epic on all counts. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week,” and received an Impact Case Award from Benchmark Litigation.
  • Representing defendants in a confidential International Chamber of Commerce (ICC) arbitration involving cross-border claims in excess of $1 billion.
  • Representing Spirits International in its dispute against the Russian Federation over the ownership of the famous Stolichnaya vodka trademarks.
  • Represented Micro Focus International (now OpenText) and certain individual defendants in securing a favorable settlement shortly before trial in putative securities class action litigation filed in New York federal court and California state court concerning its $8.8 billion acquisition of certain of Hewlett Packard Enterprise’s software assets. 
  • Represented Westpac Banking Corporation in a putative class action asserting, inter alia, antitrust, the Racketeer Influenced and Corrupt Organizations Act (RICO) and Commodity Exchange Act claims premised upon alleged manipulation of the Australian Bank Bill Swap Reference Rate (BBSW).
  • Represented Westpac Banking Corporation and its current chief executive officer in putative class action securities litigation filed in Oregon federal court alleging that Westpac failed timely to disclose that it had failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre (AUSTRAC), contrary to Australian law.
  • Represented DuPont in an antitrust class action lawsuit filed in Maryland federal court alleging that DuPont and various co‑defendants conspired to fix the price of titanium dioxide. 
  • Represented the Swedish company Folksam ömsesidig livförsäkring and won the dismissal of an action asserting RICO claims premised upon alleged violations of Swedish financial regulations, fraud and money laundering, as well as claims under the Computer Fraud and Abuse Act and New York common law.
  • Represented Chemed Corporation and various individual defendants in consolidated shareholder derivative litigation in Delaware federal court arising from alleged improper billing of Medicare and Medicaid. Mr. Cameron obtained the dismissal of that litigation once, without prejudice, and, following repleading, secured final dismissal of the matter with prejudice as to all defendants. He also represented the company in related securities class action litigation, which settled.
  • Represented Novartis Pharmaceuticals in a civil enforcement action filed in New York federal court by the U.S. Attorney’s Office for the Southern District of New York alleging violations of the False Claims Act and Anti‑Kickback Statute.
  • Represented Colgate‑Palmolive in several product liability lawsuits around the country, including two jury trials in California state court, one of which resulted in a unanimous jury verdict in Colgate-Palmolive’s favor, while the other was settled on favorable terms. Another case in South Carolina state court settled two days into trial.
  • Represented Vivendi, S.A. for over a decade in several matters, including (a) securities class action litigation which culminated in a four‑month jury trial—the first and only so‑called “foreign cubed” case to have gone to trial; (b) a four‑week jury trial over securities and contract claims in a suit brought by Liberty Media relating, in part, to a transaction involving USA Networks; and (c) a two‑day bench trial in a securities fraud case brought by GAMCO Investors—the first public market purchase case in which the presumption of reliance was successfully rebutted at a trial on the merits.
  • Represented AWB Limited (now Agrium Asia Pacific Ltd.) and won dismissals at the motion to dismiss stage of five separate actions relating to AWB’s participation in the U.N. Oil for Food Programme in Iraq and involving various claims including antitrust, civil RICO, Foreign Corrupt Practices Act (FCPA) and Alien Tort Statute claims.

Mr. Cameron’s clients commend him as a “powerful litigator” and “have nothing but the highest praise” for his work. (Best Lawyers Best Law Firms; Chambers USA) He has been recognized by Chambers USA for his work in general commercial litigation. Mr. Cameron has been selected as one of Lawdragon’s “500 Leading Lawyers in America” for over a decade, and named to several of the publication’s lists, including “100 Lawyers You Need to Know in Securities Litigation,” “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Global Litigators.” Lawdragon also named him a nationwide “Legend” in 2020.

Among other accolades, he has been recognized by Benchmark Litigation every year since 2009, including, in recent years, as a “Litigation Star” in the New York area. Mr. Cameron has been repeatedly recommended by The Legal 500 US for securities litigation and commercial litigation, as well as by The Best Lawyers in America for securities litigation, commercial litigation and international arbitration. 

Based on Mr. Cameron’s successful defense of Vivendi in the GAMCO case, Cravath was named the number one “Heavyweight Champion” in Litigation in the Financial Times 2013 U.S. Innovative Lawyers Report.

Mr. Cameron is a member of the Board of the New York International Arbitration Center, the Court of the London Court of International Arbitration (LCIA), and the Litigation Committee of the International Bar Association. 

Mr. Cameron has authored the U.S. chapter in the book The Class Action Law Review since 2017.  He has authored a chapter in the book The Dispute Resolution Review since 2010.  He was also a contributing editor of Chambers Legal Practice Guide: Litigation 2014.

Mr. Cameron was born in Auckland, New Zealand. He received an LL.B.(Hons)/B.Com in 1994 from the University of Auckland, New Zealand; an M.ComLaw with first class honors in 1997 from the University of Auckland, New Zealand; and an LL.M. in 1998 from the University of Chicago Law School. From February 1994 to September 1997, he practiced law at Russell McVeagh McKenzie Bartleet & Co. in Auckland, New Zealand.

Mr. Cameron joined Cravath in 1998 and was elected a partner in 2004.

Mr. Cameron is an experienced trial lawyer, with additional extensive experience handling antitrust, securities, shareholder derivative, M&A, and product liability claims, as well as regulatory matters. He is among the few litigators to have taken a securities case through trial, having handled three such trials for Vivendi in some of the most significant and complex securities actions in recent history. More recently, Mr. Cameron led the trial team that successfully defended the Louis Dreyfus Company and its subsidiary Imperial Sugar against the Department of Justice’s (DOJ) effort to block the sale of that company to U.S. Sugar—a significant win, that was unanimously affirmed on appeal, in one of the most closely watched antitrust cases under the Biden Administration.

Mr. Cameron also has deep experience in a wide variety of complex commercial matters, with a focus on complicated cross‑border issues particularly for non-U.S. clients.

Examples of Mr. Cameron’s current and recent cases include:

  • Represented 260 Twelfth Avenue Holdings, LLC in litigation filed in New York federal court to obtain just compensation for the taking of property through eminent domain by the National Railroad Passenger Corporation (Amtrak) in connection with the Hudson Tunnel Project in New York City, reaching a settlement shortly before a scheduled trial.
  • Led post-trial and appellate proceedings before the Fifth Circuit for Louis Dreyfus in an action brought by the Port of Houston Authority alleging Louis Dreyfus breached its agreement for the lease of a grain elevator, railroad system and surrounding infrastructure from the Port Authority. The parties reached a settlement to resolve the action.
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest acquisition in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Louis Dreyfus and its subsidiary Imperial Sugar in an action brought by the DOJ in Delaware federal court seeking to enjoin U.S. Sugar’s proposed acquisition of Imperial Sugar from Louis Dreyfus. In September 2022, the court issued a post‑trial ruling in favor of the defendants, denying the DOJ’s request for an injunction to block the acquisition, and the Third Circuit unanimously affirmed the ruling in July 2023.
  • Representing Stanley Black & Decker and current and former officers in putative class action securities litigation, as well as related consolidated shareholder derivative actions, in Connecticut federal court alleging the company made false and misleading statements concerning its tool manufacturing business.
  • Representation of Epic Games in antitrust litigation against Google, alleging anticompetitive behavior in the distribution of mobile apps and the handling of in‑app payments. Following a multiweek trial, a jury unanimously ruled in favor of Epic on all counts. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week,” and received an Impact Case Award from Benchmark Litigation.
  • Representing defendants in a confidential International Chamber of Commerce (ICC) arbitration involving cross-border claims in excess of $1 billion.
  • Representing Spirits International in its dispute against the Russian Federation over the ownership of the famous Stolichnaya vodka trademarks.
  • Represented Micro Focus International (now OpenText) and certain individual defendants in securing a favorable settlement shortly before trial in putative securities class action litigation filed in New York federal court and California state court concerning its $8.8 billion acquisition of certain of Hewlett Packard Enterprise’s software assets. 
  • Represented Westpac Banking Corporation in a putative class action asserting, inter alia, antitrust, the Racketeer Influenced and Corrupt Organizations Act (RICO) and Commodity Exchange Act claims premised upon alleged manipulation of the Australian Bank Bill Swap Reference Rate (BBSW).
  • Represented Westpac Banking Corporation and its current chief executive officer in putative class action securities litigation filed in Oregon federal court alleging that Westpac failed timely to disclose that it had failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre (AUSTRAC), contrary to Australian law.
  • Represented DuPont in an antitrust class action lawsuit filed in Maryland federal court alleging that DuPont and various co‑defendants conspired to fix the price of titanium dioxide. 
  • Represented the Swedish company Folksam ömsesidig livförsäkring and won the dismissal of an action asserting RICO claims premised upon alleged violations of Swedish financial regulations, fraud and money laundering, as well as claims under the Computer Fraud and Abuse Act and New York common law.
  • Represented Chemed Corporation and various individual defendants in consolidated shareholder derivative litigation in Delaware federal court arising from alleged improper billing of Medicare and Medicaid. Mr. Cameron obtained the dismissal of that litigation once, without prejudice, and, following repleading, secured final dismissal of the matter with prejudice as to all defendants. He also represented the company in related securities class action litigation, which settled.
  • Represented Novartis Pharmaceuticals in a civil enforcement action filed in New York federal court by the U.S. Attorney’s Office for the Southern District of New York alleging violations of the False Claims Act and Anti‑Kickback Statute.
  • Represented Colgate‑Palmolive in several product liability lawsuits around the country, including two jury trials in California state court, one of which resulted in a unanimous jury verdict in Colgate-Palmolive’s favor, while the other was settled on favorable terms. Another case in South Carolina state court settled two days into trial.
  • Represented Vivendi, S.A. for over a decade in several matters, including (a) securities class action litigation which culminated in a four‑month jury trial—the first and only so‑called “foreign cubed” case to have gone to trial; (b) a four‑week jury trial over securities and contract claims in a suit brought by Liberty Media relating, in part, to a transaction involving USA Networks; and (c) a two‑day bench trial in a securities fraud case brought by GAMCO Investors—the first public market purchase case in which the presumption of reliance was successfully rebutted at a trial on the merits.
  • Represented AWB Limited (now Agrium Asia Pacific Ltd.) and won dismissals at the motion to dismiss stage of five separate actions relating to AWB’s participation in the U.N. Oil for Food Programme in Iraq and involving various claims including antitrust, civil RICO, Foreign Corrupt Practices Act (FCPA) and Alien Tort Statute claims.

Mr. Cameron’s clients commend him as a “powerful litigator” and “have nothing but the highest praise” for his work. (Best Lawyers Best Law Firms; Chambers USA) He has been recognized by Chambers USA for his work in general commercial litigation. Mr. Cameron has been selected as one of Lawdragon’s “500 Leading Lawyers in America” for over a decade, and named to several of the publication’s lists, including “100 Lawyers You Need to Know in Securities Litigation,” “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Global Litigators.” Lawdragon also named him a nationwide “Legend” in 2020.

Among other accolades, he has been recognized by Benchmark Litigation every year since 2009, including, in recent years, as a “Litigation Star” in the New York area. Mr. Cameron has been repeatedly recommended by The Legal 500 US for securities litigation and commercial litigation, as well as by The Best Lawyers in America for securities litigation, commercial litigation and international arbitration. 

Based on Mr. Cameron’s successful defense of Vivendi in the GAMCO case, Cravath was named the number one “Heavyweight Champion” in Litigation in the Financial Times 2013 U.S. Innovative Lawyers Report.

Mr. Cameron is a member of the Board of the New York International Arbitration Center, the Court of the London Court of International Arbitration (LCIA), and the Litigation Committee of the International Bar Association. 

Mr. Cameron has authored the U.S. chapter in the book The Class Action Law Review since 2017.  He has authored a chapter in the book The Dispute Resolution Review since 2010.  He was also a contributing editor of Chambers Legal Practice Guide: Litigation 2014.

Mr. Cameron was born in Auckland, New Zealand. He received an LL.B.(Hons)/B.Com in 1994 from the University of Auckland, New Zealand; an M.ComLaw with first class honors in 1997 from the University of Auckland, New Zealand; and an LL.M. in 1998 from the University of Chicago Law School. From February 1994 to September 1997, he practiced law at Russell McVeagh McKenzie Bartleet & Co. in Auckland, New Zealand.

Mr. Cameron joined Cravath in 1998 and was elected a partner in 2004.

Education

  • LL.M., 1998, University of Chicago Law School
  • M.ComLaw, 1997, Auckland University - Faculty of Law
    First Class Honors
  • LL.B., 1994, Auckland University - Faculty of Law
  • B.Com., 1994, Auckland University - Faculty of Law

Admitted In

  • New York

Professional Affiliations

American Bar Association

Auckland District Law Society

International Bar Association

New York City Bar Association

New York State Bar Association

New Zealand Law Society

Rankings

Benchmark Litigation

  • Litigation Star ‑ New York (2025‑2016)
  • Future Star (2015‑2009)

Best Lawyers in America

  • Commercial Litigation (2025‑2014)
  • International Arbitration – Commercial (2025, 2024)
  • Litigation - Securities (2025-2019)

Chambers USA

  • Litigation: General Commercial - New York (2024)

Lawdragon

  • Legends of the 500 Leading Lawyers in America (2020)
  • 500 Leading Global Litigators (2024, 2023)
  • 100 Lawyers You Need to Know in Securities Litigation
  • 500 Leading Global Antitrust & Competition Lawyers (2025)
  • 500 Leading Lawyers in America (2025‑2011, 2008)
  • 500 Leading Litigators in America (2025, 2024, 2023)

The Legal 500 US

  • Financial Services:  Litigation (2022)
  • General Commercial (2024, 2023, 2015)
  • Securities Litigation (2023, 2019, 2018, 2017)

Super Lawyers ‑ New York

  • Business Litigation (2021‑2014)

Cleary Memorial Prize (New Zealand), 1995

Deals & Cases

October 15, 2024

Epic Games Wins Post‑Trial Injunction in Antitrust Case Against Google

On October 7, 2024, the U.S. District Court for the Northern District of California entered a post‑trial order in favor of Cravath client Epic Games imposing a nationwide three‑year permanent injunction against Google. The injunction, which follows Epic’s jury trial win against Google last year, prohibits Google from paying competitors not to compete and requires Google to distribute alternative app stores on the Google Play Store and provide alternative app stores with access to the Google Play Store’s catalog of apps.

Deals & Cases

December 19, 2023

Epic Games Defeats Google in Antitrust Trial Victory

On December 11, 2023, a jury unanimously ruled in favor of Cravath client Epic Games (“Epic”) on all counts in its closely watched antitrust case against Google in the U.S. District Court for the Northern District of California, determining—after a multiweek trial—that Google has engaged in anticompetitive behavior in the distribution of mobile apps and in the handling of in‑app payments.

Deals & Cases

September 11, 2023

Amgen Successfully Defends Against FTC Challenge, Securing Clearance for its $27.8 Billion Acquisition of Horizon Therapeutics

Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”

Deals & Cases

July 14, 2023

Louis Dreyfus Company and Imperial Sugar Company Win Appellate Victory Over DOJ

On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.

Deals & Cases

July 07, 2023

Cravath and NYU Veterans Legal Services Project Secure Win for Veteran Seeking Disability Compensation

On May 31, 2023, Judge Greenberg of the U.S. Court of Appeals for Veterans Claims ruled in favor of veteran and Cravath pro bono client Jason D. McCoy.

Activities

March 10, 2025

Benchmark Litigation Names Cravath “Antitrust Firm of the Year” at its 2025 U.S. Awards

On March 6, 2025, Benchmark Litigation honored Cravath at the publication’s sixteenth annual U.S. Awards, which was held in New York City in honor of “the elite litigators and the firms that set the standard for excellence.” The Firm was awarded Benchmark Litigation’s “Antitrust Firm of the Year” award. Cravath partners David R. Marriott and Timothy G. Cameron accepted the award on behalf of the Firm.

Publications

February 26, 2025

Tim Cameron Authors U.S. Chapter of Lexology In‑Depth’s “Dispute Resolution - Edition 17”

Cravath partner Timothy G. Cameron and associate Michael Cheng authored the United States chapter of Lexology In‑Depth’s “Dispute Resolution - Edition 17,” which was published on January 24, 2025. The chapter provides an in‑depth overview of the U.S. federal and state court systems, covering how district, bankruptcy and other special trial courts are organized, as well as the procedural rules applicable in federal courts. The chapter also reviews several notable U.S. Supreme Court decisions from 2024.

Activities

February 07, 2025

Tim Cameron Speaks at 2025 Swiss Arbitration Summit

On January 29, 2025, Cravath partner Timothy G. Cameron participated in the 2025 Swiss Arbitration Summit, which was hosted by the Swiss Arbitration Association from January 29-31 in Zurich. Tim spoke on a panel entitled “Interim Relief in Support of Arbitration: Coordination of Cross-Border Remedies Before State Courts and Arbitral Tribunals,” which brought together arbitration practitioners from multiple jurisdictions to examine the types of interim relief that can be obtained from state courts and arbitral tribunals in order to preserve the status quo until a final award is rendered.

Activities

December 19, 2023

Cravath Team Named “Litigators of the Week” by The Am Law Litigation Daily for Epic Games’ Antitrust Trial Win Defeating Google

On December 15, 2023, The Am Law Litigation Daily featured a Cravath team, led by partners Gary A. Bornstein, Lauren A. Moskowitz and Yonatan Even, as “Litigators of the Week” for its representation of client Epic Games in an antitrust trial win against Google in the U.S. District Court for the Northern District of California. Following a multi‑week trial, on December 11, 2023, a jury unanimously ruled in Epic Games’ favor on all counts, determining that Google has engaged in anticompetitive behavior in the distribution of mobile apps and in the handling of in‑app payments.

Activities

September 08, 2023

Cravath Team Named “Litigators of the Week” by The Am Law Litigation Daily for Successful Defense of Amgen Against FTC’s Challenge to Acquisition of Horizon Therapeutics

On September 8, 2023, The Am Law Litigation Daily featured a Cravath team, led by partners David R. Marriott and Timothy G. Cameron and of counsel Jesse M. Weiss, as “Litigators of the Week” for its successful defense of Amgen, one of the world’s largest biopharmaceutical companies, against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that ends all litigation and clears the path for the transaction to close.

Cravath Bicentennial

Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

Explore

Cravath, Swaine & Moore LLP Logo
  • CONTACT US
  • OUR STORY
  • ALUMNI PORTAL
  • DISCLAIMERS & NOTICES

Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.